Neurocrine Biosciences Inc

16 de out. de 2026, 19:46 UTC

Neurocrine Biosciences presents new real-world data on classic congenital adrenal hyperplasia at the Endocrine Nurses Society Annual Symposium, highlighting patient care challenges.

15 de out. de 2026, 23:11 UTC

Neurocrine Biosciences Inc is gaining in after-market trading, continuing a trend of higher closes over the past three sessions, though still below its 20-day moving average.

13 de out. de 2026, 20:01 UTC

Neurocrine Biosciences Inc declines as RBC maintains an Outperform rating and sets a price target of $187, following concerns over Vykat's safety linked to seven deaths.

12 de out. de 2026, 20:13 UTC

Neurocrine Biosciences will hold a conference call and webcast on November 2, 2026, to discuss its third quarter financial results.

9 de out. de 2026, 20:06 UTC

Neurocrine Biosciences Inc shares are modestly higher, showing a moderate upward move after earlier fluctuations, though still below its 20-day moving average.

8 de out. de 2026, 20:01 UTC

Neurocrine Biosciences Inc shares fell sharply, remaining below their 20-day moving average and near the lower end of their one-month range.

6 de out. de 2026, 19:45 UTC

Neurocrine Biosciences shares are higher as Guggenheim analyst Delma Caiati initiates coverage with a Buy rating and a $207 price target.

5 de out. de 2026, 20:20 UTC

Neurocrine Biosciences Inc is trading modestly lower in after-market hours, moving deeper into decline since Monday's close and near the lower end of its one-month range.

2 de out. de 2026, 20:07 UTC

Neurocrine Biosciences Inc is trading higher, reflecting broader market performance, though it remains below its 20-day moving average and near the lower end of its one-month range.

1 de out. de 2026, 20:07 UTC

Neurocrine Biosciences Inc shares fell modestly, closing lower after briefly peaking, and remain significantly below their 20-day moving average.

30 de set. de 2026, 20:07 UTC

Neurocrine Biosciences will present eight studies on VYKAT XR at the Foundation for Prader-Willi Research symposium, contributing to its stock's gains since Tuesday.

29 de set. de 2026, 20:07 UTC

Neurocrine Biosciences shares fell after UBS maintained its Buy rating but lowered the price target to $214 amid leadership changes.

28 de set. de 2026, 23:55 UTC

Neurocrine Biosciences shares rise in after-market trading following the return of Eiry W. Roberts, M.D., as Chief Medical Officer, ensuring continuity for late-stage programs.

25 de set. de 2026, 20:07 UTC

Neurocrine Biosciences Inc shares fell, continuing a downward trend for six sessions, significantly below the 20-day moving average amid broader market declines.

24 de set. de 2026, 20:07 UTC

Neurocrine Biosciences Inc shares fell, marking the sixth consecutive session of lower closes and remaining significantly below the 20-day moving average.

23 de set. de 2026, 20:01 UTC

Neurocrine Biosciences Inc shares fell, continuing a downward trend for four sessions and trading significantly below the 20-day moving average.

21 de set. de 2026, 20:06 UTC

Neurocrine Biosciences shares fell sharply after RBC Capital cut its price target to $187.00 from $198.00, citing concerns over near-term performance.

18 de set. de 2026, 20:02 UTC

Neurocrine Biosciences Inc shares fell sharply, breaking a trend of higher daily closes following a decline since Thursday's close.

17 de set. de 2026, 19:54 UTC

Neurocrine Biosciences Inc's stock is rising as economic data shows unexpected declines in jobless claims and stronger manufacturing growth, despite weaker housing indicators.

16 de set. de 2026, 23:51 UTC

Neurocrine Biosciences Inc is higher in after-market trading, supported by strong U.S. retail sales data, despite disappointing long-term TIC flows of $27.9 billion.

15 de set. de 2026, 23:06 UTC

Neurocrine Biosciences Inc shares are trading lower in after-market hours. Broader market conditions may be influencing sentiment amid rising inflation concerns.

10 de set. de 2026, 20:07 UTC

Neurocrine Biosciences Inc shares are advancing, supported by a steady upward trajectory. The stock remains above recent averages despite an earlier pullback.

2 de set. de 2026, 19:56 UTC

Neurocrine Biosciences Inc is trading higher today, reaching a morning high before pulling back. No specific news was identified to explain the movement.

1 de set. de 2026, 20:08 UTC

Neurocrine Biosciences Inc shares are higher today, continuing an upward trend since Monday's close amid sustained investor interest. No specific news was identified.

31 de ago. de 2026, 20:07 UTC

Neurocrine Biosciences shares are trading roughly flat amid inflation concerns and expectations for a potential interest rate hike following comments from Warsh at Jackson Hole.

28 de ago. de 2026, 20:02 UTC

Neurocrine Biosciences Inc shares are lower today, continuing a decline since Thursday amid rising U.S. Treasury yields and no specific company news identified.

27 de ago. de 2026, 20:07 UTC

Neurocrine Biosciences Inc shares are lower today, with no specific news driving the decline despite positive broader market labor data.

26 de ago. de 2026, 20:08 UTC

Neurocrine Biosciences advances after FDA accepts NBI-1117567 application, triggering a $10 million milestone payment to partner Nxera. Shares pulled back from session highs earlier.

25 de ago. de 2026, 20:07 UTC

Neurocrine Biosciences Inc shares are higher, reflecting a broader market trend amid lower oil prices and Treasury yields. The stock remains below its 20-day moving average.

24 de ago. de 2026, 22:21 UTC

Neurocrine Biosciences Inc shares are higher in after-market hours, though no specific news was identified to explain the movement. The stock remains below its 20-day moving average.